Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 5, 2017
October 22, 2020
56941716-f51b-48de-a18b-b6d0a37a66e6
Related Documents
Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products: Guidance for Industry
Guidance DocumentMay 11, 2023Center for Biologics Evaluation and Research
Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II): Guidance for Industry
Guidance DocumentFebruary 5, 2020Center for Biologics Evaluation and Research
Labeling of Red Blood Cell Units with Historical Antigen Typing Results: Guidance for Industry
Guidance DocumentDecember 20, 2018Center for Biologics Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox